BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38561695)

  • 1. Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer.
    Wu Y; Zhang J; Zhao J; Wang B
    BMC Pulm Med; 2024 Apr; 24(1):159. PubMed ID: 38561695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
    Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
    BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
    Tan D; Wang S; Zhang P; Peng C; Wu T
    Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.
    Chen H; Li F; Xue Q
    Bioengineered; 2022 Feb; 13(2):2828-2840. PubMed ID: 35068326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis.
    Hao D; Li Y; Shi J; Jiang J
    Thorac Cancer; 2023 Mar; 14(7):662-672. PubMed ID: 36691322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
    Wang X; Wang H; Jiang H; Qiao L; Guo C
    Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
    [No Abstract]   [Full Text] [Related]  

  • 17. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis.
    Ling Q; Wu S; Liao X; Liu C; Chen Y
    BMC Cancer; 2022 Jul; 22(1):765. PubMed ID: 35836137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.